Your guide to

LYTENAVA™

(bevacizumab gamma)
25 mg/mL solution for injection

LYTENAVA™ is indicated in adults for treatment of neovascular (wet) age-related macular degeneration (nAMD)

This guide is provided by Outlook Therapeutics for adult patients who have been prescribed LYTENAVA™ treatment for neovascular (wet) AMD.

UKLYT-24-005 | January 2025

LYTENAVA™
bevacizumab gamma injection

Welcome to your LYTENAVA™ guide

This document is intended to offer you information as you receive LYTENAVA™ for the treatment of neovascular (wet) AMD.

If you would like more information about LYTENAVA™ please refer to the patient information leaflet.

To access an audiovisual version of this guide, scan the QR code on the last page.

We suggest that you record your healthcare team's contact details below to make it easy for you and those supporting you to reach them when needed.

Date LYTENAVA™ was first prescribed:

Healthcare centre name:

Healthcare practitioner's name:

Healthcare practitioner's phone number:

Pharmacist's contact information:

What can you find in this guide?

This guide contains information to help you understand your condition and know what to expect with LYTENAVA™ treatment.

Summary of important safety information

Contact your doctor immediately if you experience the following symptoms:

- worsening of eye redness
- pain or increased discomfort in your eye
- increased number of floaters in your vision
- increased sensitivity to light
- blurred or decreased vision

What is neovascular AMD?

Neovascular age-related macular degeneration (nAMD), also known as wet AMD, is an eye condition that causes blurred vision and/or a blind spot in the centre of vision. It is a common cause of vision loss worldwide.

This condition develops over time due to damage of the macula (central part of the retina, situated at the back of the eye and responsible for vision):

1. Abnormal blood vessels grow into the retina
2. These vessels leak blood and fluid
3. This can be followed by possible rapid loss of central vision
4. Scarring of the macula can occur as a result

What is LYTENAVA™?

LYTENAVA™ is an anti-VEGF treatment. This means it blocks VEGF, which stands for vascular endothelial growth factor. VEGF is a protein that can cause the development of abnormal blood vessels. LYTENAVA™ targets VEGF, helping to stop the growth of abnormal blood vessels in the back of the eye.

LYTENAVA™ is a solution that is injected into your eye once every four weeks. Your doctor may change when you next receive it depending on the condition of your eye, such as your vision and the health of your eye.

Your doctor will numb your eye before injecting. You should not be able to see it. The injection is given in a small volume and is usually painless; you should only feel a little pressure during the procedure.

Who is LYTENAVA™ for?

LYTENAVA™ is for adults who have been diagnosed with neovascular (wet) AMD.

You should not be treated with LYTENAVA™ if you:

- are allergic to LYTENAVA™ or any of the other ingredients of this medicine
- have an infection in or around your eye
- have inflammation in your eye
- are pregnant or breastfeeding
- are a child or adolescent

If there is a chance you could become pregnant, you should use contraception during LYTENAVA™ treatment and for at least three months after the last injection.

If you are (or think you may be) pregnant, plan to become pregnant, or are breastfeeding, discuss this with your doctor before beginning LYTENAVA™ treatment.

What should I do before treatment?

Before your LYTENAVA™ treatment begins, it is important to tell your doctor if you have:

- recently used, are using, or might use any other medicines
- an eye condition called glaucoma, which is usually caused by high pressure in the eye
- a sudden increase in the size and number of floaters (dark floating spots) in your eye
- a history of seeing flashes of light or floaters
- had or will have eye surgery within four weeks before or after treatment
- ever had any eye diseases or eye treatments
- had blood clots, a heart attack, or a stroke
- a history of heart disease or are known to have reduced blood flow to your heart

What can I expect after treatment?

You may experience some temporary blurred vision after treatment. If this happens, you should not drive until the blurriness is gone.

You may also have a temporary rise in eye pressure within an hour of receiving LYTENAVA™. Your doctor will monitor for this after your treatment.

If you feel a little sore after your injection, speak to your doctor. They can offer you advice to help with the pain.

Does LYTENAVA™ cause any side effects?

All treatments have a risk of possible side effects. Not everyone will have side effects with LYTENAVA™, and these will vary from person to person. There may be a higher risk of side effects if LYTENAVA™ is injected into both eyes at the same time.

Contact your doctor immediately if you experience the following symptoms:

- pain or increased discomfort in your eye
- worsening eye redness
- blurred or decreased vision
- increased number of floaters in your vision
- increased sensitivity to light

What other side effects can LYTENAVA™ cause?

The most common side effects include:

- floaters, which are small particles or spots that appear in your vision
- bleeding in the protective layer covering the eye called conjunctiva
- eye pain
- increased eye pressure

What other side effects can LYTENAVA™ cause?

Uncommon side effects include:

- detachment or tear of one of the layers in the back of the eye (retinal pigment epithelial tear, vitreous detachment)
- bleeding in the eye
- inflammation of the iris, the coloured part of the eye
- inflammation or damage to the cornea, the clear layer covering the iris (keratopathy, punctate keratitis)
- corneal scar
- perceived flashes of light in the field of vision
- eye discomfort
- scratching of the cornea
- eye irritation
- itching of the eye
- dry eye
- red eye
- iodine allergy

When should I contact my doctor?

Contact your doctor immediately if you have sudden vision loss, or signs of an eye infection or inflammation, such as:

- worsening of eye redness
- pain or increased discomfort in your eye
- increased number of floaters in your vision
- increased sensitivity to light
- blurred or decreased vision

If you get any side effects after LYTENAVA™ treatment, talk to your doctor. This includes any possible side effects not listed in this leaflet. For a full list of side effects, please refer to the patient information leaflet.

We hope you have found this guide useful.
If you have any questions about your condition or treatment with LYTENAVA™, please contact your doctor or nurse.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects.

Please report side effects to the MHRA through the Yellow Card scheme. You can report via:

- the Yellow Card website www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store

Alternatively you can report a side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm.
You can leave a message outside of these hours.

When reporting please provide as much information as possible.
By reporting side effects, you can help provide more information on the safety of this medicine.

Scan the QR code or visit
patientinfo.outlooktherapeutics.com/uk
to download this guide to your device or to access
an audiovisual version of this guide.

OUTLOOK THERAPEUTICS